P.84 Managing maternal anaemia at Royal Cornwall Hospital: Iterative improvements year on year

Background: Low birth weight is the major determinant of mortality, morbidity and disability in infancy and childhood and has a long-term impact on health outcome in adult life. The objectives of this study were to study the relationship between maternal anemia and birth weight of babies and to study anthropometric measures of babies born to anemic and non-anemic mothers and to correlate the timing of anemia with birth weight of babies.Methods: Term babies born in Institute of Maternal and Child Health, Government Medical College, Kozhikode from November 2014 to October 2016 fulfilling the criteria were divided into 2 groups, cases (term babies with birth weight <2500g) and controls (term babies with weight >2500g) and studied and their maternal hemoglobin values were compared.Results: Maternal anaemia in all three trimesters was found to be more in cases compared to controls. Mean 1st trimester hemoglobin of cases was 10.68 g/dl which was significantly lower when compared to controls. Mean 2nd trimester hemoglobin of cases was 10.36 g/dl compared to 11.47 g/dl in controls. Mean 3rd trimester hemoglobin of cases was 10.42 g/dl which was also significantly lower compared to 11.32 g/dl in controls. SGA babies were also found to be more in cases, 89%, compared to 18% in controls. The difference in head circumference between two groups was not statistically significant. Mean length of babies were higher in controls compared to cases. Mothers with anemia at any time during pregnancy was found to have 4.3 times higher risk of giving birth to low birth weight babies compared to non-anemic mothersConclusion: Anemia during pregnancy is a risk factor for low birth weight and SGA, independent of the trimester. Length of babies born to anaemic mothers is also low. But it does not have a significant effect on head circumference of babies.

Download Full-text

Effect of Sulfadoxine-Pyrimethamine doses for prevention of malaria during pregnancy in hypoendemic area in Tanzania

10.21203/rs.2.19381/v2 ◽

2020 ◽

Author(s):

Wigilya Padili Mikomangwa ◽

Omary Minzi ◽

Ritah Mutagonda ◽

Vito Baraka ◽

Eulambius M. Mlugu ◽

...

Keyword(s):

Pregnant Women ◽

Malaria Transmission ◽

Geometric Mean ◽

Placental Malaria ◽

Intermittent Preventive Treatment ◽

Premature Delivery ◽

Maternal Anaemia ◽

Malaria During Pregnancy ◽

Placental Blood ◽

Low Malaria Transmission

Abstract Background Malaria in pregnancy increases the risk of deleterious maternal and birth outcomes. The use of ≥3 doses of sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria (IPTp-SP) is recommended for preventing the consequences of malaria during pregnancy. This study assessed the effect of IPTp-SP for prevention of malaria during pregnancy in low transmission settings. Methods A cross-sectional study that involved consecutively selected 1,161 pregnant women was conducted at Mwananyamala regional referral hospital in Dar es Salaam. Assessment of the uptake of IPTp-SP was done by extracting information from antenatal clinic cards. Maternal venous blood, cord blood, placental blood and placental biopsy were collected for assessment of anaemia and malaria. High performance liquid chromatography with ultraviolet detection (HPLC-UV) was used to detect and quantify sulfadoxine (SDX). Dried blood spots (DBS) of placental blood were collected for determination of sub-microscopic malaria using polymerase chain reaction (PCR). Results In total, 397 (34.2%) pregnant women reported to have used sub-optimal doses (≤2) while 764(65.8%) used optimal doses (≥3) of IPTp-SP at the time of delivery. The prevalence of placental malaria as determined by histology was 3.6%. Submicroscopic placental malaria was detected in 1.4% of the study participants. Women with peripheral malaria had six times risk of maternal anaemia than those who were malaria negative (aOR, 5.83; 95% CI, 1.10-30.92; p = 0.04). The geometric mean plasma SDX concentration was 10.76± 2.51μg/mL. Sub-optimal IPTp-SP dose was not associated with placental malaria, premature delivery and fetal anaemia. The use of ≤2 doses of IPTp-SP increased the risk of maternal anaemia by 1.36 fold compared to ≥3 doses (aOR, 1.36; 95%CI, 1.04-1.79; p = 0.02). Conclusion The use of <2 doses of IPTp-SP increased the risk of maternal anaemia. However, sub-optimal doses (≤2 doses) were not associated with increased the risk of malaria parasitaemia, fetal anaemia and preterm delivery among pregnant women in low malaria transmission setting. The use of optimal doses (≥3doses) of IPTp-SP and complementary interventions should continue even in areas with low malaria transmission.

Download Full-text